scholarly journals Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma

2016 ◽  
Vol 10 (9-10) ◽  
pp. 306
Author(s):  
Gregory W. Hosier ◽  
Matthew T. Roberts
Keyword(s):  
Renal Cell Carcinoma ◽  
Glutamic Acid ◽  
Cell Carcinoma ◽  
Metastatic Melanoma ◽  
Renal Cell ◽  
Specific Inhibitor ◽  
Initial Response ◽  
Selective Inhibitor ◽  
Complete Regression ◽  
Conventional Renal Cell Carcinoma

Vemurafenib is a selective inhibitor of overactive BRAF oncogene with a substitution of lysine for glutamic acid at residue 600 (BRAFV600E), a mutation expressed in approximately 50% of all melanomas. We report a case of a patient with metastatic melanoma treated with vemurafenib, who subsequently presented with a biopsy-proven conventional renal cell carcinoma (RCC). We observed an initial complete regression of the mass while on vemurafenib. This was unexpected, given that vemurafenib is a specific inhibitor of BRAFV600E and most RCCs do not harbour this mutation.

1111: External Validation of the Mayo Clinic SSIGN Score to Predict Cancer-Specific Survival Using a European Series of Conventional Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 357-358
Author(s):  
Vincenzo Ficarra ◽  
Christine M. Lohse ◽  
Giacomo Novara ◽  
Antonio Galfano ◽  
Stefano Cavalleri ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mayo Clinic ◽  
Renal Cell ◽  
External Validation ◽  
Cancer Specific Survival ◽  
Conventional Renal Cell Carcinoma

743: Resection of Nodal Disease in Patients with Metastatic Conventional Renal Cell Carcinoma Improves Survival

2006 ◽  
Vol 175 (4S) ◽  
pp. 241-242 ◽  
Author(s):  
Stephen Brassell ◽  
Ricardo F. Sanchez-Ortiz ◽  
Surena F. Matin ◽  
David A. Swanson ◽  
Christopher G. Wood
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Nodal Disease ◽  
Conventional Renal Cell Carcinoma

KIBRA plays as tumour suppressor via phosphorylation of LATS-2 in conventional renal cell carcinoma tissues

2021 ◽  
Vol 79 ◽  
pp. S752
Author(s):  
K. Mitsunari ◽  
Y. Miyata ◽  
T. Matsuo ◽  
K. Ohba ◽  
Y. Mukae ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumour Suppressor ◽  
Conventional Renal Cell Carcinoma

scholarly journals Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis

Oncogene ◽  
2021 ◽  
Author(s):  
Ming-xiao Zhang ◽  
Li-zhen Zhang ◽  
Liang-min Fu ◽  
Hao-hua Yao ◽  
Lei Tan ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Positive Feedback ◽  
Renal Cell ◽  
Clear Cell ◽  
Biological Significance ◽  
Specific Inhibitor ◽  
Migration And Invasion ◽  
Loss Of Function ◽  
Cell Renal Cell Carcinoma

AbstractLong noncoding RNAs (lncRNAs) have been reported to exert important roles in tumors, including clear cell renal cell carcinoma (ccRCC). PVT1 is an important oncogenic lncRNA which has critical effects on onset and development of various cancers, however, the underlying mechanism of PVT1 functioning in ccRCC remains largely unknown. VHL deficiency-induced HIF2α accumulation is one of the major factors for ccRCC. Here, we identified the potential molecular mechanism of PVT1 in promoting ccRCC development by stabilizing HIF2α. PVT1 was significantly upregulated in ccRCC tissues and high PVT1 expression was associated with poor prognosis of ccRCC patients. Both gain-of-function and loss-of function experiments revealed that PVT1 enhanced ccRCC cells proliferation, migration, and invasion and induced tumor angiogenesis in vitro and in vivo. Mechanistically, PVT1 interacted with HIF2α protein and enhanced its stability by protecting it from ubiquitination-dependent degradation, thereby exerting its biological significance. Meanwhile, HIF2α bound to the enhancer of PVT1 to transactivate its expression. Furthermore, HIF2α specific inhibitor could repress PVT1 expression and its oncogenic functions. Therefore, our study demonstrates that the PVT1/ HIF2α positive feedback loop involves in tumorigenesis and progression of ccRCC, which may be exploited for anticancer therapy.

scholarly journals Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

2021 ◽  
Vol 69 (4) ◽  
pp. 888-892
Author(s):  
Joseph I Clark ◽  
Brendan Curti ◽  
Elizabeth J Davis ◽  
Howard Kaufman ◽  
Asim Amin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Melanoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Progression Free Survival ◽  
High Dose ◽  
Free Survival

High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease control have also demonstrated improved survival compared with patients who progress, but limited data are available describing the long-term course. The aim of this study was to better characterize long-term survival following successful HD IL-2 treatment in patients with no subsequent systemic therapy. Eleven HD IL-2 treatment centers identified patients with survival ≥5 years after HD IL-2, with no subsequent systemic therapy. Survival was evaluated from the date of IL-2 treatment to June 2017. Treatment courses consisted of 2 1-week cycles of HD IL-2. Patients were treated with HD IL-2 alone, or HD IL-2 followed by local therapy to achieve maximal response. 100 patients are reported: 54 patients with mM and 46 patients with mRCC. Progression-free survival (PFS) after HD IL-2 ranges from 5+ years to 30+ years, with a median follow-up of 10+ years. 27 mRCC and 32 mM are alive ≥10 years after IL-2. Thus, a small subset of patients with mM and mRCC achieve long-term PFS (≥5 years) after treatment with HD IL-2 as their only systemic therapy. The ability of HD IL-2 therapy to induce prolonged PFS should be a major consideration in studies of new immunotherapy combinations for mM and mRCC.

scholarly journals Identification of Proteins Differentially Expressed in the Conventional Renal Cell Carcinoma by Proteomic Analysis

2005 ◽  
Vol 20 (3) ◽  
pp. 450 ◽  
Author(s):  
Jeong Seok Hwa ◽  
Hyo Jin Park ◽  
Jae Hun Jung ◽  
Sung Chul Kam ◽  
Hyung Chul Park ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Differentially Expressed ◽  
Conventional Renal Cell Carcinoma

scholarly journals CONVENTIONAL RENAL CELL CARCINOMA WITH GRANULOMATOUS REACTION

2014 ◽  
Vol 3 (48) ◽  
pp. 11626-11630
Author(s):  
Srinivas Gubbala ◽  
Satyanarayana Satyanarayana
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Granulomatous Reaction ◽  
Conventional Renal Cell Carcinoma

scholarly journals Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Melina E. Marmarelis ◽  
Meredith R. Davis ◽  
Nilay S. Sethi ◽  
Katherine M. Krajewksi ◽  
Rana R. McKay ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Melanoma ◽  
Renal Cell ◽  
Tumor Control
Sign in / Sign up

Export Citation Format

Share Document